Osteoporosis and cancer

Current Osteoporosis Reports

Volumn 11, Issue 3, 2013, Pages 163-170

  Drake, Matthew T ^a  

^a MAYO CLINIC   (United States)

Author keywords

Aromatase inhibitor; Bisphosphonate; Bone; Breast; Calcium; Cancer; Denosumab; Exercise; Myeloma; Osteoporosis; Prostate; Vitamin D

Indexed keywords

ALENDRONIC ACID; ANALGESIC AGENT; ANASTROZOLE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; ARZOXIFENE; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CORTICOSTEROID; DENOSUMAB; ESTRADIOL; GONADORELIN; GONADORELIN AGONIST; GOSERELIN; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; SEDATIVE AGENT; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEX HORMONE BINDING GLOBULIN; TAMOXIFEN; TESTOSTERONE; TOREMIFENE; ZOLEDRONIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; AGING; ALLOGENEIC STEM CELL TRANSPLANTATION; ANDROGEN DEPRIVATION THERAPY; ANTINEOPLASTIC ACTIVITY; AROMATIZATION; ARTICLE; BIOAVAILABILITY; BONE DENSITY; BONE MARROW TRANSPLANTATION; BONE METASTASIS; BONE PAIN; BONE TURNOVER; BREAST CANCER; CALCIUM ABSORPTION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PREVENTION; CASTRATION RESISTANT PROSTATE CANCER; CLIMACTERIUM; COMPRESSION FRACTURE; CONSERVATIVE TREATMENT; DISEASE ASSOCIATION; DRUG CHOICE; DRUG EFFICACY; DRUG PROTEIN BINDING; EARLY DIAGNOSIS; ELDERLY CARE; ESTRADIOL BLOOD LEVEL; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FALLING; FEMUR NECK FRACTURE; FEMUR SUBTROCHANTERIC FRACTURE; GASTRECTOMY; HEMATOLOGIC MALIGNANCY; HORMONAL REGULATION; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; JAW OSTEONECROSIS; METASTASIS FREE SURVIVAL; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; NAUSEA; NEOPLASM; ORCHIECTOMY; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; OVARY INSUFFICIENCY; PATIENT COMPLIANCE; PATIENT COUNSELING; PHYSIOTHERAPY; PREMENOPAUSE; PROSTATE CANCER; RECURRENT DISEASE; RESISTANCE TRAINING; RISK FACTOR; RISK REDUCTION; SARCOPENIA; SEX DIFFERENCE; SIDE EFFECT; SPINE FRACTURE; STOMACH CANCER; STOMACH PH; TAI CHI; TESTOSTERONE BLOOD LEVEL; VENOUS THROMBOEMBOLISM; VITAMIN SUPPLEMENTATION;

BONE RESORPTION; BREAST NEOPLASMS; FEMALE; HUMANS; INCIDENCE; MALE; NEOPLASMS; OSTEOPOROSIS; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 84885297795     PISSN: 15441873     EISSN: 15442241     Source Type: Journal    
DOI: 10.1007/s11914-013-0154-3     Document Type: Article

References (76)

1. Reuss-Borst M, Hartmann U, Scheede C, Weiss J. Prevalence of osteoporosis among cancer patients in Germany: prospective data from an oncological rehabilitation clinic. Osteoporos Int. 2012;23(4):1437-44. Prospective study of patients with multiple types of cancer demonstrating that DXA-determined osteoporosis rates are significantly higher in cancer patients compared to the general population.
2. Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350(16):1655-64.
3. Khosla S, Atkinson EJ, Melton III LJ, Riggs BL. Effects of age and estrogen status on serum parathyroid hormone levels and biochemical markers of bone turnover in women: a population-based study. J Clin Endocrinol Metab. 1997;82(5):1522-7.
4. Khosla S, Melton III LJ, Atkinson EJ, O'Fallon WM, Klee GG, Riggs BL. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab. 1998;83(7):2266-74.
5. Drake MT, Khosla S. Male osteoporosis. Endocrinol Metab Clin N Am. 2012;41(3):629-41.
6. Spangler L, Yu O, Loggers E, Boudreau DM. Bone mineral density screening among women with a history of breast cancer treated with aromatase inhibitors. J Women's Health. 2013;22(2):132-40. Retrospective study which showed that despite well-established guidelines for osteoporosis screening, many women with breast cancer treated with aromatase inhibitor therapy do not receive recommended care.
7. Ito K, Blinder VS, Elkin EB. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer. J Clin Oncol. 2012;30(13):1468-75.
8. Cardoso F, Loibl S, Pagani O, Graziottin A, Panizza P, Martincich L, et al. The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer. Eur J Cancer. 2012;48(18):3355-77.
9. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kassmann H, Piswanger-Solkner JC, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol. 2008;9(9):840-9.
10. Hershman DL, McMahon DJ, Crew KD, Shao T, Cremers S, Brafman L, et al. Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment. J Clin Endocrinol Metab. 2010;95(2):559-66.
11. Vehmanen L, Elomaa I, Blomqvist C, Saarto T. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. J Clin Oncol. 2006;24(4):675-80.
12. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005;97(22):1652-62.
13. Hadji P, Asmar L, van Nes JG, Menschik T, Hasenburg A, Kuck J, et al. The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgium sub-studies. J Cancer Res Clin Oncol. 2011;137(6):1015-25.
14. Rabaglio M, Sun Z, Price KN, Castiglione-Gertsch M, Hawle H, Thurlimann B, et al. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann Oncol. 2009;20(9):1489-98.
15. Cummings SR, McClung M, Reginster JY, Cox D, Mitlak B, Stock J, et al. Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women. J Bone Miner Res. 2011;26(2):397-404.
16. Goss PE, Ingle JN, Pritchard KI, Ellis MJ, Sledge GW, Budd GT, et al. Exemestane vs anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27 - a randomized controlled phase III trial. J Clin Oncol. 2013;31(11):1398-404. First study to demonstrate that the steroidal aromatase inhibitor exemestane was equivalent to the non-steroidal aromatase inhibitor anastrozole for breast cancer outcomes in postmenopausal women with early breast cancer, but was associated with less bone loss compared to anastrozole.
17. Amir E, Seruga B, Niraula S, Carlsson L, Ocana A. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst. 2011;103(17):1299-309.
18. Becker T, Lipscombe L, Narod S, Simmons C, Anderson GM, Rochon PA. Systematic review of bone health in older women treated with aromatase inhibitors for early-stage breast cancer. J Am Geriatr Soc. 2012;60(9):1761-7.
19. Eastell R, Adams JE, Coleman RE, Howell A, Hannon RA, Cuzick J, et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol. 2008;26(7):1051-7.
20. Cheung AM, Tile L, Cardew S, Pruthi S, Robbins J, Tomlinson G, et al. Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial. Lancet Oncol. 2012;13(3):275-84.
21. Drake MT, Cremers SC. Bisphosphonate therapeutics in bone disease: the hard and soft data on osteoclast inhibition. Mol Interv. 2010;10(3):141-52.
22. McCloskey E, Paterson A, Kanis J, Tahtela R, Powles T. Effect of oral clodronate on bone mass, bone turnover and subsequent metastases in women with primary breast cancer. Eur J Cancer. 2010;46(3):558-65.
23. Paterson AH, Anderson SJ, Lembersky BC, Fehrenbacher L, Falkson CI, King KM, et al. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol. 2012;13(7):734-42.
24. van Londen GJ, Perera S, Vujevich KT, Sereika SM, Bhattacharya R, Greenspan SL. The effect of risedronate on hip structural geometry in chemotherapy-induced postmenopausal women with or without use of aromatase inhibitors: a 2-year trial. Bone. 2010;46(3):655-9.
25. Van Poznak C, Hannon RA, Mackey JR, Campone M, Apffelstaedt JP, Clack G, et al. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol. 2010;28(6):967-75.
26. Markopoulos C, Tzoracoleftherakis E, Polychronis A, Venizelos B, Dafni U, Xepapadakis G, et al. Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. Breast Cancer Res. 2010;12(2):R24.
27. Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, et al. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med. 2011;365(15):1396-405. Large, multi-center study with a median follow-up of 59 months which showed that zoledronic acid in addition to standard adjuvant therapies did not improve disease-free survival in women with early-stage breast cancer, but was associated with an increased risk for osteonecrosis of the jaw development.
28. Coleman R, de Boer R, Eidtmann H, Llombart A, Davidson N, Neven P, et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol. 2013;24(2):398-405. Prospective, randomized study which clearly demonstrated that women with early stage breast cancer treated with zoledronic acid from time of aromatase inhibitor inititation prevented bone mineral density loss.
29. Brufsky AM, Harker WG, Beck JT, Bosserman L, Vogel C, Seidler C, et al. Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer. 2012;118(5):1192-201.
30. Llombart A, Frassoldati A, Paija O, Sleeboom HP, Jerusalem G, Mebis J, et al. Immediate administration of zoledronic acid reduces aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer: 12-month analysis of the E-ZO-FAST trial. Clin Breast Cancer. 2012;12(1):40-8.
31. Hadji P, Aapro MS, Body JJ, Bundred NJ, Brufsky A, Coleman RE, et al. Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. Ann Oncol. 2011;22(12):2546-55. Practical advice for the comprehensive management of postmenopausal women with breast cancer starting aromatase inhibitor therapy.
32. Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Fan M, et al. Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer: subgroup analyses of a phase 3 study. Breast Cancer Res Treat. 2009;118(1):81-7.
33. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28(35):5132-9. Large, randomized study which showed that in women with breast cancer complicated by bone metastases, denosumab was superior to zoledronic acid for delaying or preventing skeletal-related events, but did not change overall survival or disease progression.
34. Martin M, Bell R, Bourgeois H, Brufsky A, Diel I, Eniu A, et al. Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab vs zoledronic acid. Clin Cancer Res. 2012;18(17):4841-9.
35. Kilbreath S, Refshauge KM, Beith J, Ward L, Sawkins K, Paterson R, et al. Prevention of osteoporosis as a consequence of aromatase inhibitor therapy in postmenopausal women with early breast cancer: rationale and design of a randomized controlled trial. Contemp Clin Trials. 2011;32(5):704-9.
36. Peppone LJ, Mustian KM, Janelsins MC, Palesh OG, Rosier RN, Piazza KM, et al. Effects of a structured weight-bearing exercise program on bone metabolism among breast cancer survivors: a feasibility trial. Clin Breast Cancer. 2010;10(3):224-9.
37. Waltman NL, Twiss JJ, Ott CD, Gross GJ, Lindsey AM, Moore TE, et al. The effect of weight training on bone mineral density and bone turnover in postmenopausal breast cancer survivors with bone loss: a 24-month randomized controlled trial. Osteoporos Int. 2010;21(8):1361-9.
38. Winters-Stone KM, Dobek J, Nail L, Bennett JA, Leo MC, Naik A, et al. Strength training stops bone loss and builds muscle in postmenopausal breast cancer survivors: a randomized, controlled trial. Breast Cancer Res Treat. 2011;127(2):447-56.
39. Saarto T, Sievanen H, Kellokumpu-Lehtinen P, Nikander R, Vehmanen L, Huovinen R, et al. Effect of supervised and home exercise training on bone mineral density among breast cancer patients. A 12-month randomized controlled trial. Osteoporos Int. 2012;23(5):1601-12.
40. Brown JE, Sherriff JM, James ND. Osteoporosis in patients with prostate cancer on long-term androgen deprivation therapy: an increasing, but under-recognized problem. BJU Int. 2010;105(8):1042-3.
41. Smith MR. Obesity and sex steroids during gonadotropin-releasing hormone agonist treatment for prostate cancer. Clin Cancer Res. 2007;13(1):241-5.
42. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352(2):154-64.
43. Yu EY, Kuo KF, Gulati R, Chen S, Gambol TE, Hall SP, et al. Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer. J Clin Oncol. 2012;30(15):1864-70.
44. Alibhai SM, Yun L, Cheung AM, Paszat L. Screening for osteoporosis in men receiving androgen deprivation therapy. JAMA. 2012;307(3):255-6. Database review study demonstrating that comparatively few men initiated on androgen deprivation therapy for prostate cancer receive recommended osteoporosis screening.
45. Morgans AK, Smith MR, O'Malley AJ, Keating NL. Bone density testing among prostate cancer survivors treated with androgen-deprivation therapy. Cancer. 2013;119(4):863-70.
46. Zhumkhawala AA, Gleason JM, Cheetham TC, Niu F, Loo RK, Dell RM, et al. Osteoporosis management program decreases incidence of hip fracture in patients with prostate cancer receiving androgen deprivation therapy. Urology. 2013;81(5):1010-5. Elegant and simple study showing that in men undergoing androgen deprivation therapy for prostate cancer, the implementation of a DXA-screening program with appropriate follow-up markedly decreased hip fracture rates.
47. Choo R, Lukka H, Cheung P, Corbett T, Briones-Urbina R, Vieth R, et al. Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy. Int J Radiat Oncol Biol Phys. 2013;85(5):1239-45.
48. Greenspan SL, Nelson JB, Trump DL, Wagner JM, Miller ME, Perera S, et al. Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy. J Clin Oncol. 2008;26(27):4426-34.
49. Klotz LH, McNeill IY, Kebabdjian M, Zhang L, Chin JL. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the cancer and osteoporosis research with alendronate and leuprolide (CORAL) study. Eur Urol. 2013;63(5):927-35.
50. Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med. 2001;345(13):948-55.
51. Bhoopalam N, Campbell SC, Moritz T, Broderick WR, Iyer P, Arcenas AG, et al. Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy. J Urol. 2009;182(5):2257-64.
52. Campbell SC, Bhoopalam N, Moritz TE, Pandya M, Iyer P, Vanveldhuizen P, et al. The use of zoledronic acid in men receiving androgen deprivation therapy for prostate cancer with severe osteopenia or osteoporosis. Urology. 2010;75(5):1138-43.
53. Serpa Neto A, Tobias-Machado M, Esteves MA, Senra MD, Wroclawski ML, Fonseca FL, et al. Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2012;15(1):36-44.
54. Smith MR, Egerdie B, Hernandez Toriz N, Feldman R, Tammela TL, Saad F, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361(8):745-55.
55. Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. 2012;379(9810):39-46. Phase 3 trial demonstrating that denosumab treatment in men with castration-resistant prostate cancer provided a median 4.2 month bone-metastasis-free period versus placebo, but did not impact overall survival and was associated with a 5 % incidence of osteonecrosis of the jaw.
56. Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, et al. Denosumab vs zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377(9768):813-22. Large, multi-national, phase 3 study which showed that compared to zoledronic acid, denosumab prolonged the time to first skeletal-related-event by 3.6 months in men with castrate-resistant prostate cancer.
57. Smith MR, Morton RA, Barnette KG, Sieber PR, Malkowicz SB, Rodriguez D, et al. Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J Urol. 2013;189(1 Suppl):S45-50.
58. Smith MR, Malkowicz SB, Brawer MK, Hancock ML, Morton RA, Steiner MS. Toremifene decreases vertebral fractures in men younger than 80 years receiving androgen deprivation therapy for prostate cancer. J Urol. 2011;186(6):2239-44.
59. Smith MR, Saad F, Egerdie B, Sieber PR, Tammela TL, Ke C, et al. Sarcopenia during androgen-deprivation therapy for prostate cancer. J Clin Oncol. 2012;30(26):3271-6.
60. Clegg A, Barber S, Young J, Forster A, Iliffe S. The Home-Based Older People's Exercise (HOPE) trial: study protocol for a randomized controlled trial. Trials. 2011;12:143.
61. Culos-Reed SN, Robinson JW, Lau H, Stephenson L, Keats M, Norris S, et al. Physical activity for men receiving androgen deprivation therapy for prostate cancer: benefits from a 16-week intervention. Support Care Cancer. 2010;18(5):591-9.
62. Datta M, Schwartz GG. Calcium and vitamin D supplementation during androgen deprivation therapy for prostate cancer: a critical review. Oncologist. 2012;17(9):1171-9.
63. Alibhai SM, Mohamedali HZ, Gulamhusein H, Panju AH, Breunis H, Timilshina N, et al. Changes in bone mineral density in men starting androgen deprivation therapy and the protective role of vitamin D. Osteoporos Int. 2013. doi: 10.1007/s00198-013-2343-4
64. Ganguly S, Divine CL, Aljitawi OS, Abhyankar S, McGuirk JP, Graves L. Prophylactic use of zoledronic acid to prevent early bone loss is safe and feasible in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation. Clin Transplant. 2012;26(3):447-53.
65. Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008;111(6):2962-72.
66. Melton III LJ, Kyle RA, Achenbach SJ, Oberg AL, Rajkumar SV. Fracture risk with multiple myeloma: a population-based study. J Bone Miner Res. 2005;20(3):487-93.
67. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med. 1996;334(8):488-93.
68. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, et al. Zoledronic acid vs pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 2001;7(5):377-87.
69. Melton III LJ, Rajkumar SV, Khosla S, Achenbach SJ, Oberg AL, Kyle RA. Fracture risk in monoclonal gammopathy of undetermined significance. J Bone Miner Res. 2004;19(1):25-30.
70. Ng AC, Khosla S, Charatcharoenwitthaya N, Kumar SK, Achenbach SJ, Holets MF, et al. Bone microstructural changes revealed by high-resolution peripheral quantitative computed tomography imaging and elevated DKK1 and MIP-1alpha levels in patients with MGUS. Blood. 2011;118(25):6529-34. Study demonstrating that patients with the common pre-malignant condition monoclonal gammopathy of undetermined significance have substantial bone loss and changes in skeletal microstructure, which may explain their substantially increased fracture risk.
71. Pepe J, Petrucci MT, Mascia ML, Piemonte S, Fassino V, Romagnoli E, et al. The effects of alendronate treatment in osteoporotic patients affected by monoclonal gammopathy of undetermined significance. Calcif Tissue Int. 2008;82(6):418-26.
72. Berenson JR, Yellin O, Boccia RV, Flam M, Wong SF, Batuman O, et al. Zoledronic acid markedly improves bone mineral density for patients with monoclonal gammopathy of undetermined significance and bone loss. Clin Cancer Res. 2008;14(19):6289-95.
73. Lim JS, Jin SH, Kim SB, Lee JI. Effect of bisphosphonates on bone mineral density and fracture prevention in gastric cancer patients after gastrectomy. J Clin Gastroenterol. 2012;46(8):669-74.
74. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22(10):1479-91.
75. Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010;25(11):2267-94.
76. Khosla S, Bilezikian JP, Dempster DW, Lewiecki EM, Miller PD, Neer RM, et al. Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab. 2012;97(7):2272-82.